Literature DB >> 33580372

Quantitative proteomics analysis of Mycoplasma pneumoniae identifies potential macrolide resistance determinants.

Shaoli Li1, Guanhua Xue2, Hanqing Zhao1, Yanling Feng1, Chao Yan1, Jinghua Cui1, Xianghui Xie3, Jing Yuan4.   

Abstract

Mycoplasma pneumoniae is one of the leading causes of community-acquired pneumonia in children and adolescents. Because of the wide application of macrolides in clinical treatment, macrolide-resistant M. pneumoniae strains have become increasingly common worldwide. However, the molecular mechanisms underlying drug resistance in M. pneumoniae are poorly understood. In the present work, we analyzed the whole proteomes of macrolide-sensitive and macrolide-resistant strains of M. pneumoniae using a tandem mass tag-labeling quantitative proteomic technique, Data are available via ProteomeXchange with identifier PXD022220. In total, 165 differentially expressed proteins were identified, of which 80 were upregulated and 85 were downregulated in the drug-resistant strain compared with the sensitive strain. Functional analysis revealed that these proteins were predominantly involved in protein and peptide biosynthesis processes, the ribosome, and transmembrane transporter activity, which implicates them in the mechanism(s) of resistance of M. pneumoniae to macrolides. Our results provide new insights into drug resistance in M. pneumoniae and identify potential targets for further studies on resistance mechanisms in this bacterium.

Entities:  

Keywords:  Differentially expressed proteins; Drug resistance; Mycoplasma pneumoniae; Quantitative proteomic technique; Whole proteomes

Year:  2021        PMID: 33580372     DOI: 10.1186/s13568-021-01187-8

Source DB:  PubMed          Journal:  AMB Express        ISSN: 2191-0855            Impact factor:   3.298


  37 in total

1.  Occurrence of macrolide-resistant Mycoplasma pneumoniae strains in Germany.

Authors:  R Dumke; H von Baum; P C Lück; E Jacobs
Journal:  Clin Microbiol Infect       Date:  2009-09-17       Impact factor: 8.067

2.  Complete sequence analysis of the genome of the bacterium Mycoplasma pneumoniae.

Authors:  R Himmelreich; H Hilbert; H Plagens; E Pirkl; B C Li; R Herrmann
Journal:  Nucleic Acids Res       Date:  1996-11-15       Impact factor: 16.971

3.  Presence of the arginine dihydrolase pathway in Mycoplasma.

Authors:  M F Barile; R T Schimke; D B Riggs
Journal:  J Bacteriol       Date:  1966-01       Impact factor: 3.490

4.  In vitro low-level resistance to azoles in Candida albicans is associated with changes in membrane lipid fluidity and asymmetry.

Authors:  Avmeet Kohli; Kasturi Mukhopadhyay; Ashok Rattan; Rajendra Prasad
Journal:  Antimicrob Agents Chemother       Date:  2002-04       Impact factor: 5.191

Review 5.  Antimicrobial therapy of macrolide-resistant Mycoplasma pneumoniae pneumonia in children.

Authors:  Hyunju Lee; Ki Wook Yun; Hoan Jong Lee; Eun Hwa Choi
Journal:  Expert Rev Anti Infect Ther       Date:  2017-12-11       Impact factor: 5.091

6.  The lipid composition of azole-sensitive and azole-resistant strains of Candida albicans.

Authors:  C A Hitchcock; K J Barrett-Bee; N J Russell
Journal:  J Gen Microbiol       Date:  1986-09

Review 7.  Overview of antimicrobial options for Mycoplasma pneumoniae pneumonia: focus on macrolide resistance.

Authors:  Bin Cao; Jiu-Xin Qu; Yu-Dong Yin; Johan Van Eldere
Journal:  Clin Respir J       Date:  2015-10-13       Impact factor: 2.570

8.  Macrolide resistance in Staphylococcus aureus: induction of macrolide-resistant protein synthesis.

Authors:  N E Allen
Journal:  Antimicrob Agents Chemother       Date:  1977-04       Impact factor: 5.191

9.  Complete Genome Sequence of the Macrolide-Resistant Mycoplasma pneumoniae Strain C267 in China.

Authors:  Shaoli Li; Hongmei Sun; Fei Liu; Hanqing Zhao; Baoli Zhu; Na Lv
Journal:  Genome Announc       Date:  2016-04-07

Review 10.  Mycoplasma pneumoniae: A Potentially Severe Infection.

Authors:  Bharat Bajantri; Sindhaghatta Venkatram; Gilda Diaz-Fuentes
Journal:  J Clin Med Res       Date:  2018-06-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.